Myers Squibb – Talk Bio

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos

3 weeks ago talkbio0Tagged Aficamten, Approved, Camzyos, Cytokinetics, Hypertrophic obstructive cardiomyopathy, Myers Squibb, Myqorzo, United States Food and Drug Administration

FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

3 weeks ago talkbio0Tagged biobucks, Burning Mouth Syndrome, China, Clinical Trials, global strategic collaboration, Harbour BioMed, Harbour Mice ® technology, Immunology, License Agreement, milestones, multi-specific antibodies, Myers Squibb, Neoplasms

Harbour BioMed; Bristol Myers Squibb; BMS; multi-specific antibodies; $90 million upfront; $1.035 billion milestones; global strategic collaboration; license agreement; Harbour Mice technology; immunology; oncology; biobucks deal; China early clinical trials

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

1 month ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, BREAST-01, disease control rate, Gene Expression, Myers Squibb, ORR, PD-L1, PD-L1xVEGF-A, Phase 2 trial, Progression-Free Survival, pumitamig, ROSETTA, SABCS, TNBC, Triple Negative Breast Neoplasms

BioNTech; Bristol Myers Squibb; pumitamig; BNT327; PD-L1xVEGF-A bispecific antibody; Phase 2 trial; triple-negative breast cancer; TNBC; confirmed ORR; disease control rate; progression-free survival; PD-L1 expression; ROSETTA BREAST-01; SABCS

Bristol Myers Squibb Delays Cobenfy Alzheimer’s Psychosis Trial Readout Due to Site Irregularities

1 month ago talkbio0Tagged ADEPT-2 trial, Alzheimer 's psychosis, Cobenfy, Deferred, Myers Squibb, Phase 3 Clinical Trials, trial site irregularities

Bristol Myers Squibb; Cobenfy; Alzheimer’s psychosis; ADEPT-2 trial; trial site irregularities; Phase III study; delay; 2026

Spotlight On: Big Pharma’s Big Bets on In Vivo Cell Therapy

2 months ago talkbio0Tagged AbbVie, Acquisition, AstraZeneca, Autoimmune Diseases, CAR-T, Cell Therapy, gene therapy, Gilead, in vivo, Manufacturing, Myers Squibb, scalability

in vivo cell therapy; CAR-T; acquisition; autoimmune disease; gene therapy; manufacturing; scalability; Bristol Myers Squibb; Gilead; AbbVie; AstraZeneca

BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant

2 months ago talkbio0Tagged Anticoagulants, BMS-986177, Clinical Trial Termination, coronary trial, Factor XIa inhibitor, Janssen, Myers Squibb

Bristol Myers Squibb; Johnson & Johnson; Janssen; anticoagulant; Factor XIa inhibitor; BMS-986177; coronary trial; clinical trial termination

BMS Battles Deeply Ingrained Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates

2 months ago talkbio0Tagged Alzheimer 's disease, Antipsychotic Agents, Cobenfy, Dopamine D2 Receptor, Drug Kinetics, drug market, earnings, Myers Squibb, prescribing habits, Psychotic Disorders, Schizophrenia, Trimonthly, Uptake

Bristol Myers Squibb; Cobenfy; schizophrenia; prescribing habits; dopamine D2 receptor; novel mechanism of action; quarterly earnings; drug market uptake; Alzheimer’s disease psychosis; atypical antipsychotics

Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics

3 months ago talkbio0Tagged Acquisition, Autoimmune Diseases, Automobiles, Cell Therapy, immune system reprogramming, in vivo, Myers Squibb, NUSAP1 gene, Obstetric Delivery, Orbital Therapeutics, OTX-201, RNA medicines, RNA, Circular, T-cell therapy

Bristol Myers Squibb; Orbital Therapeutics; in vivo CAR T-cell therapy; autoimmune diseases; RNA medicines; OTX-201; cell therapy; acquisition; LNP delivery; circular RNA; immune system reprogramming

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

3 months ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer